Cardiovasc Diabetol Endocrinol
GLP-1s reduce heart attacks, strokes, and death even without diabetes
Clinical Takeaway: The cardiovascular benefit of GLP-1s appears independent of glycemic control. Prescribers can consider these agents for heart risk reduction in high-risk patients, not just for metabolic management.
Questions have persisted about whether the cardiovascular protection offered by GLP-1 receptor agonists reflects true cardioprotection or simply better metabolic control. This meta-analysis pooled data from 11 large randomized cardiovascular outcome trials to test whether the benefit is durable, consistent, and broader than glycemic improvement alone.
The answer across all three questions was yes. Treatment reduced major adverse cardiovascular events, a composite of MI, stroke, and cardiovascular death, by 14% compared with placebo. Reductions extended to cardiovascular and all-cause mortality, non-fatal MI, non-fatal stroke, and hospitalization for heart failure.
A sensitivity analysis excluding the SELECT trial, the only study enrolling patients without diabetes, produced nearly identical results, suggesting metabolic improvement doesn't fully explain the benefit. A subgroup analysis of four semaglutide trials showed a somewhat stronger effect than the overall class estimate, though that finding was post-hoc and should be considered hypothesis-generating.
Researchers analyzed data from trials published between 2016 and 2025 on drugs including semaglutide, liraglutide, dulaglutide, albiglutide, and exenatide. All trials had at least 3,000 participants and 12 months of follow-up; median follow-up was 2.7 years.
The consistency of benefit across drug formulations, trial designs, and patient populations — including those without diabetes — points toward a direct cardiovascular mechanism, possibly involving endothelial function, inflammation, and atherosclerotic pathways.
That distinction matters for how these drugs are positioned in treatment guidelines and risk reduction strategies, and it's already reflected in FDA approvals. Several GLP-1 receptor agonists are FDA-approved for cardiovascular risk reduction. This includes semaglutide (Wegovy) for adults with obesity or overweight and established heart disease, alongside semaglutide (Ozempic/Rybelsus), liraglutide (Victoza), and dulaglutide (Trulicity) for the prevention of major cardiac events in adults with type 2 diabetes and high cardiovascular risk.
"Our results show that, when taken over a prolonged period of at least one year, these medications do much more than help control blood sugar or weight. They significantly reduce the risk of heart attacks, strokes and premature death in people who are already vulnerable," said Simon Cork, PhD, physiology lead at Anglia Ruskin University's School of Medicine. “We found the benefits to be consistent across different drugs, trial designs and patient groups. This has important implications for clinical practice and health policy.”
He concluded, “These drugs have the potential to become a key part of healthcare strategies, especially for people with type 2 diabetes or established heart disease. Using them earlier and more widely across populations could help prevent thousands of serious cardiovascular events.”
Source: Peter K, et al. Cardiovasc Diabetol Endocrinol Rep. 2026 May 1. The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis